Search hospitals > Colorado > Lafayette
Kaiser Permanente-Rock Creek
Claim this profileLafayette, Colorado 80026
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
99 reported clinical trials
2 medical researchers
Summary
Kaiser Permanente-Rock Creek is a medical facility located in Lafayette, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Kaiser Permanente-Rock Creek is involved with conducting 99 clinical trials across 264 conditions. There are 2 research doctors associated with this hospital, such as Alexander Menter and Debra P. Ritzwoller.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Alexander MenterKaiser Permanente-Franklin5 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
73 drugs studied
Debra P. RitzwollerKaiser Permanente-Franklin1 year of reported clinical research
Studies Cancer
Studies Blood Cancers
2 reported clinical trials
2 drugs studied
Clinical Trials running at Kaiser Permanente-Rock Creek
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Cutaneous Melanoma
Melanoma
Squamous Cell Carcinoma
Skin Cancer
Tumors
Blood Cancers
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-Rock Creek?
Kaiser Permanente-Rock Creek is a medical facility located in Lafayette, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Kaiser Permanente-Rock Creek is involved with conducting 99 clinical trials across 264 conditions. There are 2 research doctors associated with this hospital, such as Alexander Menter and Debra P. Ritzwoller.